Invention Grant
- Patent Title: Bioerodible implant for long-term drug delivery and associated methods of manufacture and use
-
Application No.: US17531658Application Date: 2021-11-19
-
Publication No.: US11833244B2Publication Date: 2023-12-05
- Inventor: John H. Baillie , Ruth Baillie , George Blouin , Newsha Farahani , Christopher Marx
- Applicant: Gesea Biosciences Inc.
- Applicant Address: US CA San Luis Obispo
- Assignee: Gesea Biosciences Inc.
- Current Assignee: Gesea Biosciences Inc.
- Current Assignee Address: US CA San Luis Obispo
- Agency: VLP Law Group LLP
- Agent Dianne E. Reed
- The original application number of the division: US15720921 2017.09.29
- Main IPC: A61K9/00
- IPC: A61K9/00 ; A61K31/567 ; A61K47/36 ; A61K9/50 ; A61F6/08 ; A61F6/22 ; A61K31/167 ; A61K31/325 ; A61K31/57 ; A61K31/593 ; A61K47/10 ; A61K47/12 ; A61K47/24 ; A61K47/28 ; A61K31/192 ; A61F2/30 ; A61L27/54 ; A61L27/58
Abstract:
A drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a pharmacologically active agent over an extended time period. As such, the drug delivery system finds significant utility in chronic drug administration. Bioerosion products are water soluble, bioresorbed, or both, obviating the need for surgical removal of the implant. Methods for manufacturing and using the drug delivery system are also provided.
Public/Granted literature
- US20220249365A1 BIOERODIBLE IMPLANT FOR LONG-TERM DRUG DELIVERY AND ASSOCIATED METHODS OF MANUFACTURE AND USE Public/Granted day:2022-08-11
Information query
